

**November 10, 2021**

**BSE Limited**

25<sup>th</sup> Floor, P J Towers,  
Dalal Street, Fort,  
Mumbai- 400 001  
Scrip Code: 531637

Dear Sirs,

**Sub. : Submission of Consolidated and Standalone Unaudited Financial Results for the quarter and half-year ended September 30, 2021**

---

In continuation of our letter dated November 2, 2021 and pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we enclose the Unaudited Financial Results (Consolidated and Standalone) for the quarter and half-year ended September 30, 2021, duly reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company, at their respective meetings held today.


The meeting of the Board of Directors commenced at 4:00 p.m. and concluded at 5:25 p.m.

Kindly acknowledge the receipt.

Thanking You,

Yours Faithfully,

**For Praveg Communications (India) Limited**  
(Formerly known as Sword and Shield Pharma Limited)



**Mukesh Chaudhary**  
Company Secretary &  
Compliance Officer



Encl. : As Above

**PRAVEG COMMUNICATIONS (INDIA) LIMITED**

(Formerly Sword and Shield Pharma Limited in which Praveg Communications Limited has amalgamated)

Regd. Office: 214, Athena Avenue, Behind Jaguar Showroom, S. G. Highway, Gota, Ahmedabad-382481

CIN: L24231GJ1995PLC024809 | Phone: +91 79 27496737 | Email: info@praveg.com | Website: www.praveg.com

Ahmedabad | New Jersey | Atlanta | Sydney



**Independent Auditor's Limited Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

Review Report to,  
The Board of Directors,  
**PRAVEG COMMUNICATIONS (INDIA) LIMITED**  
(Formerly Known as Sword and Shield Pharma Limited)  
Ahmedabad

1. We have reviewed the accompanying statement of unaudited Consolidated Financial Results (the statements) together with the relevant notes thereon of **Praveg Communications (India) Limited** (Formerly Known as Sword and Shield Pharma Limited), Ahmedabad (the "Holding Company") together with its 2 Subsidiaries and 1 Joint Venture (together referred to as "the Group") for the quarter ended September 30, 2021 and year to date from April 1, 2021 to September 30, 2021 ("the Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ('Ind AS 34') "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.
5. The Statement includes the results of the following entities:


Subsidiary	Joint Venture
Praveg Communications (USA) Inc	SardarSarovar Tourism Opportunities
Praveg Communications AUS Pty Ltd	



6. The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of 2 subsidiaries and 1 joint venture, whose unaudited interim financial results and other financial information reflect total revenues Nil for the quarter ended September 30, 2021 and for the period from April 1, 2021 to September 30, 2021, as considered in the Statement whose interim financial results and other financial information have not been reviewed by their auditors. These unaudited interim financial results and other unaudited financial information have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries and joint venture are based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.
7. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of consolidated unaudited financial results prepared in accordance with Indian accounting standards ('Ind AS 34') as specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, B. K. PATEL & CO  
Chartered Accountants  
Firm Regn No. 112647W



  
K. D. Patel  
Partner

Membership No. 039919  
UDIN: 21039919AAAAHB2719

Ahmedabad  
10-11-2021

**PRAVEG COMMUNICATIONS (INDIA) LIMITED**

(FORMERLY KNOWN AS SWORD AND SHIELD PHARMA LIMITED)

Regd Office: 214, Athena Avenue, Behind Jaguar Showroom, S. G. Highway, Gota, Ahmedabad GJ 382481 IN

CIN: L24231GJ1995PLC024809

Website :- www.praveg.com

Email Id:- cs@praveg.com

**Statement of Consolidated Financial Results for the quarter/ half year ended September 30, 2021**

(Rs. in Lakh except per share data)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30-09-2021	30-06-2021	30-09-2020	30-09-2021	30-09-2020	31-03-2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1 INCOME</b>						
i Revenue From Operations	891.34	363.18	341.45	1,254.52	537.45	4,531.52
ii Other Income	0.13	2.65	12.69	2.78	30.66	33.37
<b>Total Income</b>	<b>891.47</b>	<b>365.83</b>	<b>354.14</b>	<b>1,257.30</b>	<b>568.11</b>	<b>4,564.89</b>
<b>2 Expenses</b>						
i Event & Site Expenses	422.48	160.02	123.22	582.50	153.84	2,256.34
ii Employee Benefit Expenses	111.58	96.99	78.19	208.57	171.21	377.38
iii Finance Costs	14.07	10.64	3.91	24.71	9.23	33.47
iv Depreciation and Amortisation Expense	69.54	25.73	33.74	95.27	68.18	164.10
v Other Expenses	47.46	20.78	55.14	68.24	93.16	307.17
<b>Total Expenses</b>	<b>665.13</b>	<b>314.16</b>	<b>294.20</b>	<b>979.29</b>	<b>495.62</b>	<b>3,138.46</b>
<b>3 Profit / (Loss) before loss of share of Joint venture, exceptional items and Tax</b>	<b>226.34</b>	<b>51.67</b>	<b>59.94</b>	<b>278.01</b>	<b>72.49</b>	<b>1,426.43</b>
4 Share of Profit/(loss) from joint venture	0.00	0.00	0.01	0.00	0.01	0.01
<b>5 Profit / (Loss) before exceptional items and Tax</b>	<b>226.34</b>	<b>51.67</b>	<b>59.95</b>	<b>278.01</b>	<b>72.50</b>	<b>1,426.44</b>
6 Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
<b>7 Profit / ( Loss ) before Tax</b>	<b>226.34</b>	<b>51.67</b>	<b>59.95</b>	<b>278.01</b>	<b>72.50</b>	<b>1,426.44</b>
<b>8 Tax Expense</b>	<b>57.00</b>	<b>13.05</b>	<b>13.62</b>	<b>70.05</b>	<b>17.66</b>	<b>352.38</b>
i Current Tax	57.00	13.05	13.62	70.05	17.66	375.20
ii Deferred Tax	0.00	0.00	0.00	0.00	0.00	(22.82)
<b>9 Profit (Loss) for the period from continuing operations</b>	<b>169.34</b>	<b>38.62</b>	<b>46.33</b>	<b>207.96</b>	<b>54.84</b>	<b>1,074.06</b>
i Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
ii Tax expenses of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
<b>10 Profit for the Year / Period</b>	<b>169.34</b>	<b>38.62</b>	<b>46.33</b>	<b>207.96</b>	<b>54.84</b>	<b>1,074.06</b>
<b>11 Other Comprehensive Income</b>						
a Items that will not be reclassified to profit or loss						
i) Remeasurement of defined employee benefit plans	0.00	0.00	0.00	0.00	0.00	5.33
ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	(1.34)
<b>Total Other Comprehensive Income (Net of Tax)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>3.99</b>
<b>12 Total comprehensive income for the year/ Period</b>	<b>169.34</b>	<b>38.62</b>	<b>46.33</b>	<b>207.96</b>	<b>54.84</b>	<b>1,078.05</b>
13 Paid-up equity share capital [Face value, Rs.10 per share]	1,848.41	1,848.41	1,848.41	1,848.41	1,848.41	1,848.41
14 Total Reserves						57.33
<b>15 Earnings per equity share [Basic + Diluted] *</b>	<b>0.92</b>	<b>0.21</b>	<b>0.25</b>	<b>1.13</b>	<b>0.30</b>	<b>5.83</b>
* Quarterly EPS are not Annualised						

**PRAVEG COMMUNICATIONS (INDIA) LIMITED**

(Formerly Known as Sword and Shield Pharma Limited)

Regd Office: 214, Athena Avenue, Behind Jaguar Showroom, S. G. Highway, Gota, Ahmedabad GJ 382481 IN

CIN: L24231GJ1995PLC024809 Website :- www.praveg.com Email Id:- cs@praveg.com

**Consolidated Unaudited Statement of Assets and Liability**

(Rs. In Lakh)

Particulars	As at 30.09.2021	As at 31.03.2021
	(Unaudited)	(Audited)
<b>Assets</b>		
<b>1 Non-current Assets</b>		
(a) Property, Plant and Equipment	611.25	218.53
(b) Right-of-use assets	277.47	318.17
(c) Other Intangible Assets	3.49	3.72
(d) Financial Assets		
(i) Non Current Investment	9.74	9.74
(ii) Other Non-Current Financial Assets	14.17	33.08
(e) Deferred Tax Assets (Net)	45.70	45.70
(f) Other Non Current Assets	0.00	0.00
<b>Total Non-current Assets</b>	<b>961.82</b>	<b>628.94</b>
<b>2 Current Assets</b>		
(a) Inventories	424.64	428.52
(b) Financial Assets		
(i) Trade Receivables	1,137.79	581.26
(ii) Cash and Cash Equivalents	30.96	914.49
(iii) Other Bank Balance	26.75	4.94
(iv) Current Loans	1.75	13.11
(v) Other Financial Assets	33.18	13.95
(c) Current Tax Assets (Net)	9.37	9.35
(c) Other Current Assets	50.90	103.61
<b>Total Current Assets</b>	<b>1,715.34</b>	<b>2,069.23</b>
<b>Total Assets</b>	<b>2,677.16</b>	<b>2,698.17</b>
<b>Equity and liabilities</b>		
<b>1 Equity</b>		
(a) Equity Share Capital	1,848.41	1,848.41
(b) Other Equity	(104.32)	57.33
(c) Non-controlling interest	0.00	0.00
<b>Total Equity</b>	<b>1,744.09</b>	<b>1,905.74</b>
<b>2 Non-current Liabilities</b>		
(a) Financial Liabilities		
(i) Non-current Borrowings	48.31	16.03
(ii) Lease Liabilities	216.86	221.69
(b) Long Term Provisions	20.71	20.71
<b>Total Non-current Liabilities</b>	<b>285.88</b>	<b>258.43</b>
<b>3 Current Liabilities</b>		
(a) Financial Liabilities		
(i) Current Borrowings	247.59	72.72
(ii) Lease Liabilities	70.97	68.78
(iii) Trade Payables	138.27	276.81
(b) Current tax liabilities (net)	6.08	0.00
(c) Short Term Provisions	85.45	83.14
(d) Other Current Liabilities	98.83	32.55
<b>Total Current Liabilities</b>	<b>647.19</b>	<b>534.00</b>
<b>Total Liabilities</b>	<b>933.07</b>	<b>792.43</b>
<b>Total Equity and Liabilities</b>	<b>2,677.16</b>	<b>2,698.17</b>

**PRAVEG COMMUNICATIONS (INDIA) LIMITED**

(Formerly Known as Sword and Shield Pharma Limited)

Regd Office: 214, Athena Avenue, Behind Jaguar Showroom, S. G. Highway, Gota, Ahmedabad GJ 382481 IN

CIN: L24231GJ1995PLC024809

Website :- www.praveg.com

Email Id:- cs@praveg.com

**Consolidated Unaudited Cash Flow Statement**

(Rs. In Lakh)

Particulars	For the half year ended on 30.09.2021	For the half year ended on 30.09.2020
	(Unaudited)	(Unaudited)
<b>(A) CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit before tax	278.01	72.50
Adjustments for:		
Depreciation and Amortisation Expense	95.27	68.18
Interest income	(2.78)	(1.08)
Foreign Exchange Gain	0.04	(0.13)
Finance cost	24.71	9.23
Loss on sale of Assets	0.00	2.24
Profit on sale of Shares	0.00	(8.23)
Sundry Balances Written off / (written back)	0.78	(19.69)
Adjustment of Error as per Ind AS 08 in Opening Balance	0.00	(10.89)
Operating profits before working capital changes	396.03	112.13
<b>Changes in working capital</b>		
Decrease (Increase ) in Inventories	3.88	(64.03)
Decrease (Increase ) in Trade Receivables	(556.53)	535.32
Decrease (increase) in other assets	32.70	21.98
Increase (Decrease) in Trade payables	(138.53)	(393.22)
Increase (Decrease ) in other liabilities and provisions	68.59	93.59
	<b>(589.89)</b>	<b>193.64</b>
Cash generated from operations	<b>(193.86)</b>	<b>305.77</b>
Taxes (paid)	(63.99)	(50.41)
<b>Net Cash generated from (used in) operating activities</b>	<b>(257.85)</b>	<b>255.36</b>
<b>(B) CASH FLOW FROM INVESTING ACTIVITIES</b>		
Capital expenditure on Property, plant and equipments, including Capital work in progress and capital advances	(447.04)	(4.49)
(Investments)/ Disinvestments in Subsidiaries	0.00	(0.02)
Bank deposit / margin money withdrawn (net)	(2.90)	1.00
Loan received/ (Given) back from Subsidiaries	0.00	(0.75)
Loan received/ (Given) back from others	11.36	(122.32)
Profit on Sale of Shares in Subsidiaries	0.00	8.23
Interest received	2.78	1.08
Effect of Minority interest	0.00	(10.46)
<b>Net Cash generated (used in) from Investing activities</b>	<b>(435.80)</b>	<b>(127.73)</b>
<b>(C) CASH FLOW FROM FINANCING ACTIVITIES</b>		
Net Proceeds from (Repayment) of current borrowings	174.87	213.79
Net Proceeds from (Repayment) Lease Liability	(2.64)	0.00
Net Proceeds / (Repayment ) of Non-current borrowings	32.28	(39.76)
Finance cost paid	(24.71)	(9.23)
Dividend on Equity Shares	(369.68)	(277.26)
<b>Net Cash generated (used in) Financing activities</b>	<b>(189.88)</b>	<b>(112.46)</b>
<b>Net increase in Cash &amp; Cash equivalents (A+B+C)</b>	<b>(883.53)</b>	<b>15.17</b>
Cash and Cash equivalents at the beginning of the period	914.49	277.14
Cash and Cash equivalents at the end of the period	<b>30.96</b>	<b>292.31</b>

**PRAVEG COMMUNICATIONS (INDIA) LIMITED**

(FORMERLY KNOWN AS SWORD AND SHIELD PHARMA LIMITED)

Regd Office: 214, Athena Avenue, Behind Jaguar Showroom, S.G. Highway, Gota, Ahmedabad GJ 382481

CIN: L24231GJ1995PLC024809


Website :- www.praveg.com

Email Id:- cs@praveg.com

**Notes forming part of consolidated financial results;**

- 1 The Audit Committee has reviewed, and the Board of Directors has approved the above results at their respective meetings held on November 10, 2021. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- 2 The above consolidated financial results of the company have been prepared in accordance with Indian Accounting Standard as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
- 3 The Outbreak of Coronavirus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activities. The Company's Operations and Revenue were impacted due to COVID-19, However, it has no further significant impact with respect to COVID-19 pandemic during the quarter and half year ended on September 30, 2021.
- 4 The figures for the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable for the users of the financial statements.
- 5 Revenue from operations includes unbilled sale of service of Rs.113.10 Lakhs.

For and on behalf of the Board of Directors of  
**Praveg Communications (India) Limited**



Date: 10-11-2021

**Paraskumar M. Patel**

Place: Ahmedabad

Managing Director




**Independent Auditor's Limited Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**


Review Report to,  
The Board of Directors,  
**PRAVEG COMMUNICATIONS (INDIA) LIMITED**  
(Formerly Known as Sword and Shield Pharma Limited)  
Ahmedabad

1. We have reviewed the accompanying statement of unaudited Standalone Financial Results (the statements) together with the relevant notes thereon of **Praveg Communications (India) Limited** (Formerly Known as Sword and Shield Pharma Limited), Ahmedabad for the quarter ended September 30, 2021 and year to date from April 1, 2021 to September 30, 2021 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, have been prepared in accordance with *the recognition and measurement* principles laid down in Indian Accounting Standard 34, ('Ind AS 34') "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by Independent Auditor of Entity" issued by The Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with Indian accounting standards ('Ind AS') as specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, B. K. PATEL & CO  
Chartered Accountants  
Firm Regn No. 112647W



Ahmedabad  
10-11-2021

  
K. D. Patel  
Partner  
Membership No. 039919  
UDIN: 21039319AAAAHA9214



**PRAVEG COMMUNICATIONS (INDIA) LIMITED**

(FORMERLY KNOWN AS SWORD AND SHIELD PHARMA LIMITED)

Regd Office: 214, Athena Avenue, Behind Jaguar Showroom, S. G. Highway, Gota, Ahmedabad GJ 382481 IN

CIN: L24231GJ1995PLC024809

Website :- www.praveg.com

Email Id:- cs@praveg.com

**Statement of Standalone Financial Results for the quarter/ Half year ended September 30, 2021**

(Rs. in Lakh except per share data)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30-09-2021	30-06-2021	30-09-2020	30-09-2021	30-09-2020	31-03-2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1 INCOME</b>						
i Revenue From Operations	891.34	363.18	336.95	1,254.52	532.95	4,527.05
ii Other Income	0.13	2.65	12.69	2.78	30.66	42.60
<b>Total Income</b>	<b>891.47</b>	<b>365.83</b>	<b>349.64</b>	<b>1,257.30</b>	<b>563.61</b>	<b>4,569.65</b>
<b>2 Expenses</b>						
i Event & Site Expenses	422.48	160.02	123.22	582.50	157.04	2,256.34
ii Employee Benefit Expenses	111.58	96.99	78.19	208.57	171.21	377.38
iii Finance Costs	14.08	10.62	3.85	24.70	9.16	33.41
iv Depreciation and Amortisation Expense	69.54	25.73	33.74	95.27	68.18	164.10
v Other Expenses	47.44	20.63	55.14	68.07	89.77	306.15
<b>Total Expenses</b>	<b>665.12</b>	<b>313.99</b>	<b>294.14</b>	<b>979.11</b>	<b>495.36</b>	<b>3,137.38</b>
<b>3 Profit / (Loss) before loss of share of Joint venture, exceptional items and Tax</b>	<b>226.35</b>	<b>51.84</b>	<b>55.50</b>	<b>278.19</b>	<b>68.25</b>	<b>1,432.27</b>
4 Share of Profit /(loss) from joint venture	0.00	0.00	0.00	0.00	0.00	0.00
<b>5 Profit / (Loss) before exceptional items and Tax</b>	<b>226.35</b>	<b>51.84</b>	<b>55.50</b>	<b>278.19</b>	<b>68.25</b>	<b>1,432.27</b>
6 Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
<b>7 Profit / ( Loss ) before Tax</b>	<b>226.35</b>	<b>51.84</b>	<b>55.50</b>	<b>278.19</b>	<b>68.25</b>	<b>1,432.27</b>
<b>8 Tax Expense</b>	<b>57.00</b>	<b>13.05</b>	<b>13.62</b>	<b>70.05</b>	<b>17.71</b>	<b>352.38</b>
i Current Tax	57.00	13.05	13.62	70.05	17.71	375.20
ii Deferred Tax	0.00	0.00	0.00	0.00	0.00	(22.82)
<b>9 Profit (Loss) for the period from continuing operations</b>	<b>169.35</b>	<b>38.79</b>	<b>41.88</b>	<b>208.14</b>	<b>50.54</b>	<b>1,079.89</b>
i Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
ii Tax expenses of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
<b>10 Profit for the Period/ Year</b>	<b>169.35</b>	<b>38.79</b>	<b>41.88</b>	<b>208.14</b>	<b>50.54</b>	<b>1,079.89</b>
<b>11 Other Comprehensive Income</b>						
a Items that will not be reclassified to profit or loss						
i) Remeasurement of defined employee benefit plans	0.00	0.00	0.00	0.00	0.00	5.33
ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	(1.34)
<b>Total Other Comprehensive Income (Net of Tax)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>3.99</b>
<b>12 Total comprehensive income for the Period/ Year</b>	<b>169.35</b>	<b>38.79</b>	<b>41.88</b>	<b>208.14</b>	<b>50.54</b>	<b>1,083.88</b>
13 Paid-up equity share capital [Face value, Rs.10 per share]	1,848.41	1,848.41	1,848.41	1,848.41	1,848.41	1,848.41
14 Total Reserves						67.43
<b>15 Earnings per equity share [Basic + Diluted] *</b>	<b>0.92</b>	<b>0.21</b>	<b>0.23</b>	<b>1.13</b>	<b>0.27</b>	<b>5.86</b>

\* Quarterly EPS are not Annualised

**PRAVEG COMMUNICATIONS (INDIA) LIMITED**

(Formerly Known as Sword and Shield Pharma Limited)

Regd Office: 214, Athena Avenue, Behind Jaguar Showroom, S. G. Highway, Gota, Ahmedabad GJ 382481 IN

CIN: L24231GJ1995PLC024809

Website :- www.praveg.com

Email Id:- cs@praveg.com

**Standalone Unaudited Statement of Assets and Liabilities**

(Rs. In Lakh)

Particulars	As at 30.09.2021	As at 31.03.2021
	(Unaudited)	(Audited)
<b>Assets</b>		
<b>1 Non-current Assets</b>		
(a) Property, Plant and Equipment	611.25	218.53
(b) Right-of-use assets	277.47	318.17
(c) Other Intangible Assets	3.49	3.72
(d) Financial Assets		
(i) Non Current Investment	20.67	20.67
(ii) Other Non-Current Financial Assets	14.17	33.08
(e) Deferred Tax Assets (Net)	45.70	45.70
<b>Total Non-current Assets</b>	<b>972.75</b>	<b>639.87</b>
<b>2 Current Assets</b>		
(a) Inventories	424.64	428.52
(b) Financial Assets		
(i) Trade Receivables	1,137.79	581.26
(ii) Cash and Cash Equivalents	25.64	911.15
(iii) Other Bank Balance	26.75	4.94
(iv) Current Loans	3.89	15.34
(v) Other Financial Assets	33.18	13.95
(c) Current Tax Assets (Net)	9.37	9.35
(c) Other Current Assets	50.90	103.61
<b>Total Current Assets</b>	<b>1,712.16</b>	<b>2,068.12</b>
<b>Total Assets</b>	<b>2,684.91</b>	<b>2,707.99</b>
<b>Equity and liabilities</b>		
<b>1 Equity</b>		
(a) Equity Share Capital	1,848.41	1,848.41
(b) Other Equity	(94.09)	67.43
<b>Total Equity</b>	<b>1,754.32</b>	<b>1,915.84</b>
<b>2 Non-current Liabilities</b>		
(a) Financial Liabilities		
(i) Non-current Borrowings	48.31	16.03
(ii) Lease Liabilities	216.86	221.69
(b) Long Term Provisions	20.71	20.71
<b>Total Non-current Liabilities</b>	<b>285.88</b>	<b>258.43</b>
<b>3 Current Liabilities</b>		
(a) Financial Liabilities		
(i) Current Borrowings	245.14	72.43
(ii) Lease Liabilities	70.97	68.78
(iii) Trade Payables	138.24	276.82
(b) Current tax liabilities (net)	6.08	0.00
(c) Short Term Provisions	85.45	83.14
(d) Other Current Liabilities	98.83	32.55
<b>Total Current Liabilities</b>	<b>644.71</b>	<b>533.72</b>
<b>Total Liabilities</b>	<b>930.59</b>	<b>792.15</b>
<b>Total Equity and Liabilities</b>	<b>2,684.91</b>	<b>2,707.99</b>

**PRAVEG COMMUNICATIONS (INDIA) LIMITED**  
(Formerly Known as Sword and Shield Pharma Limited)

Regd Office: 214, Athena Avenue, Behind Jaguar Showroom, S. G. Highway, Gota, Ahmedabad GJ 382481 IN

CIN: L24231GJ1995PLC024809

Website :- www.praveg.com

Email Id:- cs@praveg.com

**Standalone Unaudited Cash Flow Statement**

(Rs. In Lakh)

Particulars	For the half year ended on 30.09.2021	For the half year ended on 30.09.2020
	(Unaudited)	(Unaudited)
<b>(A) CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit before tax	278.19	68.25
Adjustments for:		
Depreciation and Amortisation Expense	95.27	68.18
Interest income	(2.78)	(1.08)
Finance costs	24.70	9.16
Loss on sale of assets	0.00	2.24
Profit on sale of Shares	0.00	(8.23)
Sundry Balances Written off / (written back)	0.78	(19.69)
Operating profits before working capital changes	396.16	118.83
<b>Changes in working capital</b>		
Decrease (Increase ) in Inventories	3.88	(64.03)
Decrease (Increase ) in Trade Receivables	(556.53)	417.72
Decrease (increase) in other assets	32.70	21.94
Increase (Decrease) in Trade payables	(138.58)	(391.77)
Increase (Decrease ) in other liabilities and provisions	68.59	90.36
	<b>(589.94)</b>	<b>74.22</b>
<b>Cash generated from operations</b>	<b>(193.78)</b>	<b>193.05</b>
Taxes (paid)	(63.99)	(49.84)
<b>Net Cash generated from (used in) operating activities</b>	<b>(257.77)</b>	<b>143.21</b>
<b>(B) CASH FLOW FROM INVESTING ACTIVITIES</b>		
Capital expenditure on Property, plant and equipments, including Capital work in progress and capital advances	(447.04)	(4.49)
(Investments)/ DisInvestments in Subsidiaries	0.00	0.49
Bank deposit / margin money withdrawan (net)	(2.90)	1.00
Loan received/ (Given) back from Subsidiaries	0.09	121.12
Loan received/ (Given) back from others	11.36	(122.32)
Profit on Sale of Shares in Subsidiaries	0.00	8.23
Interest received	2.78	1.08
<b>Net Cash generated (used in) from Investing activities</b>	<b>(435.71)</b>	<b>5.11</b>
<b>(C) CASH FLOW FROM FINANCING ACTIVITIES</b>		
Net Proceeds from (Repayment) of current borrowings	172.71	213.79
Net Proceeds from (Repayment) Lease Liability	(2.64)	0.00
Net Proceeds / (Repayment ) of Non current borrowings	32.28	(39.76)
Finance cost paid	(24.70)	(9.16)
Dividend paid on Equity Shares	(369.68)	(277.26)
<b>Net Cash generated (used in) Financing activities</b>	<b>(192.03)</b>	<b>(112.39)</b>
<b>Net increase in Cash &amp; Cash equivalents (A+B+C)</b>	<b>(885.51)</b>	<b>35.93</b>
<b>Cash and Cash equivalents at the beginning of the period</b>	<b>911.15</b>	<b>252.22</b>
<b>Cash and Cash equivalents at the end of the period</b>	<b>25.64</b>	<b>288.15</b>

**PRAVEG COMMUNICATIONS (INDIA) LIMITED**

(FORMERLY KNOWN AS SWORD AND SHIELD PHARMA LIMITED)

Regd Office: 214, Athena Avenue, Behind Jaguar Showroom, S.G. Highway, Gota, Ahmedabad GJ 382481

CIN: L24231GJ1995PLC024809


Website :- www.praveg.com

Email Id:- cs@praveg.com

**Notes forming part of standalone financial results;**

- 1 The Audit Committee has reviewed, and the Board of Directors has approved the above results at their respective meetings held on November 10, 2021. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- 2 The above standalone financial results of the company have been prepared in accordance with Indian Accounting Standard as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
- 3 The Outbreak of Coronavirus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activities. The Company's Operations and Revenue were impacted due to COVID-19, However, it has no further significant impact with respect to COVID-19 pandemic during the quarter and half year ended on September 30, 2021.
- 4 The figures for the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable for the users of the financial statements.
- 5 Revenue from operations includes unbilled sale of service of Rs.113.10 Lakhs.

For and on behalf of the Board of Directors of  
**Praveg Communications (India) Limited**



**Paraskumar M. Patel**  
Managing Director

Date: 10-11-2021

Place: Ahmedabad